-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Selpercatinib (Sepetinib) is a highly effective and first selective broad-spectrum anticancer drug targeting the RET proto-oncogene.
NSCLC
In the global phase 1/2 LIBRETTO-001 trial (NCT03157128), patients with advanced solid tumors with RET variants were treated with Selpercatinib at a dose of 160 mg, 2/day, orally, 28 days as a course of treatment
This article reports the results of the analysis of RET fusion-positive NSCLC patients with intracranial metastases at baseline
There are a total of 80 NSCLC patients with intracranial metastases at baseline
Intracranial ORR
Intracranial ORRIn 22 patients with measurable intracranial lesions at baseline, the intracranial ORR was 82% (95% CI 60-95), including 23% complete remission
Intracranial ORR was 82%.
Intracranial PFS
Intracranial PFSAt 12 months, 55% of patients in intracranial remission were still continuing treatment
At a median follow-up of 11.
In summary, Selpercatinib has a strong and long-lasting intracranial effect in patients with RET fusion-positive NSCLC
Original source:
Vivek Subbiah, et al.
Intracranial Efficacy of Selpercatinib in RET Fusion- Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
in this message
